ME02101B - Pročišćavanje antitijela hromatografijom izmjene katjona - Google Patents
Pročišćavanje antitijela hromatografijom izmjene katjonaInfo
- Publication number
- ME02101B ME02101B MEP-2015-34A MEP3415A ME02101B ME 02101 B ME02101 B ME 02101B ME P3415 A MEP3415 A ME P3415A ME 02101 B ME02101 B ME 02101B
- Authority
- ME
- Montenegro
- Prior art keywords
- cation exchange
- antibody
- exchange material
- washing
- buffer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Claims (15)
1. Postupak za pročišćavanje antitela iz sastava koji sadrži antitelo i najmanje jedan zagađivač, gde postupak obuhvata sledeće uzastopne korake:a)nanošenje sastava na materijal izmene katjona, gde je sastav na početku na pH od 4,0 do 6,0;b)ispiranje materijala izmene katjona prvim puferom za ispiranje, gde je pH prvog pufera za ispiranje od 6,8 do 9,0;c)ispiranje materijala izmene katjona drugim puferom za ispiranje pri pH od 5,0 do 6,0; id)eluciju antitela iz materijala izmene katjona puferom za eluciju na provodnosti koja je najmanje 2 mS/cm veća od one kod drugog pufera za ispiranje.
2. Postupak prema patentnom zahtevu 1 gde su pH drugog pufera za ispiranje i pH pufera za eluciju približno isti.
3. Postupak prema patentnom zahtevu 1 gde se antitelo vezuje na humani CD20.
4. Postupak prema patentnom zahtevu 1 gde se antitelo vezuje na humani vaskularni endotelni faktor rasta (VEGF).
5. Postupak prema patentnom zahtevu 1 gde je pH sastava kod (a) od 4,0 do 6,0, pH prvog pufera za ispiranje je od 6,8 do 8,0, pH drugog pufera za ispiranje od 5,0 do 6.0, a pH pufera za eluciju je od 5,0 do 6,0.
6. Postupak prema patentnom zahtevu 1 gde je provodnost pufera za eluciju od 10 mS/cm do 100 mS/cm.
7. Postupak prema patentnom zahtevu 1 gde se pufer za eluciju sastoji od 100 do 300 mM NaCl.
8. Postupak prema patentnom zahtevu 1, gde materijal izmene katjona sadrži unakrsno spojene poli(stiren-divinilbenzen) protočne čestice obložene polihidroksiliranim polimerom koji je funkcionalizovan sulfopropil grupama.
9. Postupak prema patentnom zahtevu 1 gde je zagađivač odabran iz grupe koja se sastoji od proteina jajnih ćelija kineskog hrčka (CHOP), izlučenog proteina A, DNK, nagomilanih antitela, komponente medijuma ćelijske kulture, garamicina i virusnih zagađenja.
10. Postupak za pročišćavanje antitela koje vezuje humani CD20 iz sastava koji sadrži antitelo i jedan ili više zagađivač odabranih iz skupine koja se sastoji od proteina jajnih ćelija kineskog hrčka (CHOP), ispranog proteina A, DNK, nagomilanoih CD20 antitela, gde postupak obuhvata sledeće uzastopne korake: a)nanošenje sastava na materijal izmene katjona, gde je sastav na pH od 4,0 do 6,0; b)ispiranje materijala izmene katjona prvom puferom za ispiranje na 6,8 do 9,0; c)ispiranje materijala izmene katjona drugim puferom za ispiranje pri pH od 5,0 do 6,0; i d)eluciju antitela iz materijala izmene katjona puferom za eluciju sa ph od 5,0 do 6,0 i provodnosti od 10 mS/cm do 100 mS/cm.
11. Postupak prema patentnom zahtevu 10 gde je antitelo rituksimab.
12. Postupak prema patentnom zahtevu 10 gde se pufer za eluciju sastoji od 100 do 300 mM NaCl.
13. Postupak za pročišćavanje antitela koje vezuje humani vaskularni endotelni faktor rasta (VEGF) iz sastava koji sadrži antitelo i jedan ili više zagađivača odabranih iz grupe koja se sastoji od komponente medijuma ćelijske kulture, garamicina, proteina jajnih ćelija kineskog hrčka (CHOPS) DNK, virusnih zagađivača i nagomilanih VEGF antitela, gde postupak obuhvata sledeće uzastopne korake: a)nanošenje sastava na materijal izmene katjona, gde je sastav na pH od 4,0 do 6,0; b)ispiranje materijala izmene katjona prvom puferom za ispiranje na 6,8 do 8,0; c)ispiranje materijala izmene katjona drugim puferom za ispiranje pri pH od 5,0 do 6,0; i d)eluciju antitela iz materijala izmene katjona puferom za eluciju sa ph od 5,0 do 6,0 i provodnosti od 10 mS/cm do 100 mS/cm.
14. Postupak prema patentnom zahtevu 13 gde je antitelo bevacizumab.
15. Postupak prema patentnom zahtevu 13 gde se pufer za eluciju sastoji od 100 do 300 mM NaCl.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98382507P | 2007-10-30 | 2007-10-30 | |
| PCT/US2008/081516 WO2009058812A1 (en) | 2007-10-30 | 2008-10-29 | Antibody purification by cation exchange chromatography |
| EP08844379.1A EP2215117B2 (en) | 2007-10-30 | 2008-10-29 | Antibody purification by cation exchange chromatography |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02101B true ME02101B (me) | 2015-10-20 |
Family
ID=40262967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-34A ME02101B (me) | 2007-10-30 | 2008-10-29 | Pročišćavanje antitijela hromatografijom izmjene katjona |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20090148435A1 (me) |
| EP (4) | EP2565206B1 (me) |
| JP (5) | JP5237382B2 (me) |
| KR (3) | KR101241486B1 (me) |
| CN (3) | CN101889025B (me) |
| AR (2) | AR069097A1 (me) |
| AU (1) | AU2008318865B2 (me) |
| BR (1) | BRPI0817182A2 (me) |
| CA (1) | CA2703279C (me) |
| CL (1) | CL2008003218A1 (me) |
| CO (1) | CO6280422A2 (me) |
| CY (1) | CY1116129T1 (me) |
| DK (3) | DK2840090T3 (me) |
| ES (3) | ES2666170T3 (me) |
| HK (1) | HK1221234A1 (me) |
| HR (2) | HRP20150282T4 (me) |
| HU (3) | HUE024877T2 (me) |
| IL (4) | IL205310A0 (me) |
| ME (1) | ME02101B (me) |
| MX (1) | MX2010004740A (me) |
| NZ (1) | NZ584839A (me) |
| PE (1) | PE20091434A1 (me) |
| PH (1) | PH12013501128A1 (me) |
| PL (3) | PL2215117T5 (me) |
| PT (1) | PT2215117E (me) |
| RS (1) | RS53850B2 (me) |
| RU (1) | RU2498991C2 (me) |
| SG (2) | SG10201401690XA (me) |
| SI (3) | SI2565206T1 (me) |
| TW (2) | TWI554517B (me) |
| WO (1) | WO2009058812A1 (me) |
| ZA (2) | ZA201002850B (me) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA2592177A1 (en) * | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| TWI456062B (zh) | 2006-09-13 | 2014-10-11 | Abbvie Inc | 細胞培養改良 |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| CN101889025B (zh) | 2007-10-30 | 2013-11-13 | 健泰科生物技术公司 | 通过阳离子交换层析进行的抗体纯化 |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| AU2009347206C1 (en) | 2008-10-20 | 2016-12-08 | Abbvie Inc. | Isolation and purification of antibodies using Protein A affinity chromatography |
| MX2011004201A (es) | 2008-10-20 | 2011-05-24 | Abbott Lab | Desactivacion viral durante purificacion de anticuerpos. |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP2480561B1 (en) | 2009-09-23 | 2016-07-13 | E. R. Squibb & Sons, L.L.C. | Cation exchange chromatography |
| KR102104197B1 (ko) * | 2010-02-23 | 2020-04-24 | 제넨테크, 인크. | 난소암의 치료를 위한 항혈관신생 요법 |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| HUE036157T2 (hu) * | 2010-03-30 | 2018-06-28 | Janssen Biotech Inc | Humanizált IL-25 ellenanyagok |
| PT3351636T (pt) | 2010-05-14 | 2020-09-24 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos |
| EP4492053A3 (en) | 2010-05-25 | 2025-03-19 | F. Hoffmann-La Roche AG | Methods of purifying polypeptides |
| GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
| KR101574864B1 (ko) | 2010-12-21 | 2015-12-11 | 에프. 호프만-라 로슈 아게 | 이소폼이 농축된 항체 제제 및 그의 제조 방법 |
| KR102058254B1 (ko) * | 2011-03-29 | 2019-12-20 | 글락소스미스클라인 엘엘씨 | 단백질 정제용 완충제 시스템 |
| WO2012160530A1 (en) * | 2011-05-26 | 2012-11-29 | Dr. Reddy's Laboratories Limited | Purification of antibodies |
| CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| WO2013054250A1 (en) * | 2011-10-10 | 2013-04-18 | Dr Reddy's Laboratories Limited | Purification method |
| WO2013055874A2 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| RU2478646C1 (ru) * | 2011-11-28 | 2013-04-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) | Способ получения высокоаффинных поликлональных антител |
| RU2648999C2 (ru) | 2011-12-22 | 2018-03-29 | Дженентек, Инк. | Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии |
| LT3495387T (lt) | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
| EP2889617B1 (en) * | 2012-08-27 | 2017-10-11 | Asahi Kasei Medical Co., Ltd. | Antibody purification method by means of temperature-responsive chromatography |
| CN103217499B (zh) * | 2013-01-15 | 2015-12-02 | 珠海市丽珠单抗生物技术有限公司 | 一种测定免疫球蛋白电荷异构体的糖基化和末端修饰情况的方法 |
| SG10201709131UA (en) | 2013-03-08 | 2017-12-28 | Genzyme Corp | Continuous purification of therapeutic proteins |
| UY35517A (es) | 2013-04-04 | 2014-10-31 | Mabxience S A | Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína |
| RU2019115089A (ru) | 2013-04-16 | 2019-06-11 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| US10351592B2 (en) | 2013-10-30 | 2019-07-16 | Celltrion, Inc. | Method for separating antibody isoforms using cation exchange chromatography |
| CN104628846B (zh) * | 2013-11-06 | 2019-12-06 | 三生国健药业（上海）股份有限公司 | 重组蛋白质的纯化方法 |
| WO2015077605A1 (en) | 2013-11-25 | 2015-05-28 | Seattle Genetics, Inc. | Preparing antibodies from cho cell cultures for conjugation |
| TWI671312B (zh) | 2014-01-17 | 2019-09-11 | 美商健臻公司 | 無菌層析法及製法 |
| TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
| KR102382402B1 (ko) | 2014-02-04 | 2022-04-01 | 바이오젠 엠에이 인코포레이티드 | 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도 |
| ES2784749T3 (es) | 2014-03-10 | 2020-09-30 | Richter Gedeon Nyrt | Purificación de inmunoglobulina con el uso de etapas de limpieza previa |
| CN105017418B (zh) * | 2014-03-27 | 2021-02-23 | 上海药明康德新药开发有限公司 | 单克隆抗体纯化工艺方法 |
| JP2017513901A (ja) | 2014-04-25 | 2017-06-01 | ジェネンテック， インコーポレイテッド | トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法 |
| KR102403547B1 (ko) | 2014-07-16 | 2022-05-30 | 오레곤 헬스 앤드 사이언스 유니버시티 | 외인성 항원을 포함하는 인간 시토메갈로바이러스 |
| CN105315369B (zh) * | 2014-07-25 | 2020-03-13 | 山东博安生物技术有限公司 | 利用阳离子交换层析纯化蛋白质 |
| KR102490956B1 (ko) * | 2015-03-13 | 2023-01-19 | 브리스톨-마이어스 스큅 컴퍼니 | 불순물을 제거하기 위한 크로마토그래피 동안의 알칼리성 세척의 용도 |
| US11406715B2 (en) | 2015-05-30 | 2022-08-09 | Genentech, Inc. | Methods of treating HER2-positive metastatic breast cancer |
| KR101657690B1 (ko) * | 2015-06-05 | 2016-09-19 | 주식회사 녹십자홀딩스 | 혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법 |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| AU2016355468B2 (en) | 2015-11-20 | 2022-12-15 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| GB201600512D0 (en) | 2016-01-12 | 2016-02-24 | Univ York | Recombinant protein production |
| JP7046828B2 (ja) | 2016-04-15 | 2022-04-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 滲出型加齢性黄斑変性の治療のための組成物 |
| WO2017197199A1 (en) * | 2016-05-13 | 2017-11-16 | Askgene Pharma Inc. | Novel angiopoietin 2, vegf dual antagonists |
| HRP20202077T1 (hr) * | 2016-07-15 | 2021-02-19 | F. Hoffmann - La Roche Ag | Postupak za pročišćavanje pegiliranog eritropoetina |
| CN106222222B (zh) * | 2016-08-08 | 2019-10-29 | 湖北医药学院 | 一种重组人白血病抑制因子的制备方法 |
| WO2018045587A1 (zh) * | 2016-09-12 | 2018-03-15 | 广东东阳光药业有限公司 | 一种抗vegf类单克隆抗体的纯化方法 |
| CN106380519B (zh) * | 2016-10-17 | 2019-11-01 | 深圳万乐药业有限公司 | 一种单克隆抗体的纯化方法 |
| CN110036112B (zh) | 2016-10-18 | 2024-05-10 | 俄勒冈健康与科学大学 | 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体 |
| WO2018078158A1 (en) * | 2016-10-31 | 2018-05-03 | Hexal Ag | Antibody preparation |
| AU2017387909A1 (en) | 2016-12-28 | 2019-06-27 | Genentech, Inc. | Treatment of advanced HER2 expressing cancer |
| SG11201905622VA (en) | 2017-01-17 | 2019-08-27 | Genentech Inc | Subcutaneous her2 antibody formulations |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| BE1025090B1 (fr) | 2017-03-30 | 2018-10-29 | Univercells Sa | Procede et kit de purification de proteines |
| TWI679209B (zh) * | 2017-04-14 | 2019-12-11 | 南韓商Ｃｊ醫藥健康股份有限公司 | 使用陽離子交換層析法純化同功抗體之方法 |
| EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
| JP2020525445A (ja) * | 2017-06-21 | 2020-08-27 | セファロン・インコーポレイテッドＣｅｐｈａｌｏｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | カチオン交換クロマトグラフィーの洗浄緩衝液 |
| JP2020534332A (ja) * | 2017-09-22 | 2020-11-26 | イミュノジェン， インコーポレイテッド | カチオン交換クロマトグラフィーを使用した三重軽鎖抗体の分離 |
| US12558434B2 (en) | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| CN110272491B (zh) * | 2018-03-13 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体的纯化工艺 |
| WO2019191416A1 (en) * | 2018-03-29 | 2019-10-03 | Bristol-Myers Squibb Company | Methods of purifying monomeric monoclonal antibodies |
| CN112105927B (zh) * | 2018-05-08 | 2024-06-25 | 沃特世科技公司 | 可用于pH梯度阳离子交换色谱法的方法、组合物和试剂盒 |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| HK40046210A (en) | 2018-08-31 | 2021-10-29 | Genzyme Corporation | Sterile chromatography resin and use thereof in manufacturing processes |
| EP3643322A1 (en) * | 2018-10-26 | 2020-04-29 | Mabion SA | Low aggregate anti cd20 ligand formulation |
| EP3873519A1 (en) | 2018-10-29 | 2021-09-08 | F. Hoffmann-La Roche AG | Antibody formulation |
| CN109320611B (zh) * | 2018-10-31 | 2022-06-03 | 鼎康(武汉)生物医药有限公司 | 一种人鼠嵌合单克隆抗体生物类似药的纯化方法 |
| CN112206327A (zh) * | 2019-07-12 | 2021-01-12 | 上海药明生物技术有限公司 | 一种抗体偶联药物的制备及其高通量筛选方法 |
| KR20220079844A (ko) * | 2019-10-14 | 2022-06-14 | 피어스 바이오테크놀로지, 인크 | 펩티드 정제 제제 및 방법 |
| CN114651007A (zh) * | 2019-11-07 | 2022-06-21 | 安进公司 | 阳离子交换色谱期间的高盐洗涤以去除产品相关的杂质 |
| US20230027029A1 (en) * | 2019-11-25 | 2023-01-26 | Akeso Biopharma, Inc. | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof |
| KR102153258B1 (ko) * | 2020-02-21 | 2020-09-07 | 프레스티지바이오로직스 주식회사 | 베바시주맙 정제의 최적화된 방법 |
| BR112022019042A2 (pt) * | 2020-03-25 | 2022-11-01 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Método de preparação para conjugado anticorpo-fármaco |
| AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
| US11416468B2 (en) * | 2020-07-21 | 2022-08-16 | International Business Machines Corporation | Active-active system index management |
| KR20240102971A (ko) | 2021-11-16 | 2024-07-03 | 제넨테크, 인크. | 모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물 |
| CN114591438B (zh) * | 2022-04-25 | 2023-12-05 | 达石药业(广东)有限公司 | 一种采用阳离子交换层析法纯化双特异性抗体的方法 |
| EP4609878A4 (en) * | 2022-10-26 | 2026-04-08 | Nihon Mediphysics Co Ltd | PROCESS FOR THE PRODUCTION OF RADIOACTIVE PHARMACEUTICAL COMPOSITION |
| CN115850493B (zh) * | 2022-11-08 | 2024-03-12 | 江苏耀海生物制药有限公司 | 一种二价纳米抗体Cablivi的分离纯化方法 |
| CN117756878A (zh) * | 2023-12-26 | 2024-03-26 | 康日百奥生物科技(苏州)有限公司 | 抗体层析分离方法及应用 |
| WO2025193804A1 (en) * | 2024-03-12 | 2025-09-18 | Massachusetts Eye And Ear Infirmary | Methods and materials for treating ocular neovascular diseases |
| WO2025232755A1 (zh) * | 2024-05-07 | 2025-11-13 | 南京蓬勃生物科技有限公司 | 一种使用阳离子交换层析纯化目标蛋白的方法 |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
| GB2070818A (en) | 1980-02-04 | 1981-09-09 | Philips Electronic Associated | Regulated power supply for an image intensifier |
| WO1984002129A1 (fr) | 1982-11-22 | 1984-06-07 | Takeda Chemical Industries Ltd | Proteine de l'interferon immun humain et son procede de preparation |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5169774A (en) * | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| WO1986002068A1 (fr) | 1984-09-26 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Separation mutuelle de proteines |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US5196323A (en) | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US5525338A (en) * | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| CA1283072C (en) * | 1986-12-01 | 1991-04-16 | Timothy Durance | Process for the isolation and separation of lysozyme and avidin from eggwhite |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5451662A (en) * | 1987-10-23 | 1995-09-19 | Schering Corporation | Method of purifying protein |
| US5118796A (en) | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| IT1219874B (it) | 1988-03-18 | 1990-05-24 | Fidia Farmaceutici | Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche |
| US5115101A (en) | 1988-06-08 | 1992-05-19 | Miles Inc. | Removal of protein A from antibody preparations |
| EP0420937B1 (en) | 1988-06-21 | 1994-11-09 | Genentech, Inc. | Therapeutic compositions for the treatment of myocardial infarction |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5112951A (en) * | 1989-07-28 | 1992-05-12 | Hybritech Incorporated | Separation of anti-metal chelate antibodies |
| US5110913A (en) * | 1990-05-25 | 1992-05-05 | Miles Inc. | Antibody purification method |
| EP0467466A1 (en) * | 1990-07-16 | 1992-01-22 | Eastman Kodak Company | Method for the purification of immunoreactive labeled thyroxine conjugates |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| CA2113813C (en) | 1991-08-14 | 2005-04-12 | Paula M. Jardieu | Immunoglobulin variants for specific fc epsilon receptors |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| JPH05202098A (ja) | 1992-01-29 | 1993-08-10 | Snow Brand Milk Prod Co Ltd | 乳質原料から生理活性物質の製造法 |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| US5279823A (en) | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
| WO1994004188A1 (en) | 1992-08-21 | 1994-03-03 | Genentech, Inc. | Method for treating an lfa-1-mediated disorder |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| DK0733207T3 (da) | 1993-12-10 | 1998-04-20 | Genentech Inc | Fremgangsmåder til diagnose af allergi og screening af anti-allergi-terapeutika |
| DK0739214T3 (da) | 1994-01-18 | 1998-10-07 | Genentech Inc | Fremgangsmåde til behandling af parasitinfektionerunder anvendelse af IgE antagonister |
| US5429746A (en) * | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5702946A (en) | 1994-03-03 | 1997-12-30 | Genentech, Inc. | Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| IL125255A (en) | 1996-01-23 | 2002-02-10 | Genentech Inc | Anti-cd18 antibodies for treating stroke |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| ES2293662T3 (es) | 1996-11-15 | 2008-03-16 | Genentech, Inc. | Purificacion de neurotrofinas. |
| EP0950067B1 (en) | 1996-11-27 | 2007-08-29 | Genentech, Inc. | Affinity purification of polypeptide on protein a matrix |
| WO1998023761A1 (en) | 1996-11-27 | 1998-06-04 | Genentech, Inc. | HUMANIZED ANTI-CD11a ANTIBODIES |
| EP2338915A3 (en) | 1997-04-07 | 2011-10-12 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| EP0981618B2 (en) | 1997-05-15 | 2011-08-24 | Genentech, Inc. | Anti-apo-2 antibody |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| PT1308456E (pt) | 1998-05-06 | 2007-12-03 | Genentech Inc | Purificação de anticorpos por cromatografia de permuta iónica |
| EP1500661A1 (en) | 1998-06-01 | 2005-01-26 | Genetech, Inc. | Separation of protein monomers from aggregates by use of ion-exchange chromatography |
| NZ509135A (en) | 1998-06-09 | 2002-10-25 | Statens Seruminstitut | A third generation intravenous immunoglobulin G (IVIG) purified using column chromatographic ion exchange methods |
| CA2376596C (en) | 1999-06-25 | 2009-10-06 | Genentech, Inc. | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
| AU778199B2 (en) | 1999-10-29 | 2004-11-25 | Genentech Inc. | Anti-prostate stem cell antigen (PSCA) antibody compositions and methods of use |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| US6417355B1 (en) | 2001-04-11 | 2002-07-09 | The United States Of America As Represented By The Secretary Of The Navy | Geminal-dinitro-1-5 diazocine derivatives |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| US6770027B2 (en) * | 2001-10-05 | 2004-08-03 | Scimed Life Systems, Inc. | Robotic endoscope with wireless interface |
| EP1507793A4 (en) | 2001-10-17 | 2006-02-01 | Human Genome Sciences Inc | NEUTROKIN ALPHA AND NEUTROKIN ALPHA SPLICE VERSION |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| KR101033196B1 (ko) | 2002-02-14 | 2011-05-09 | 이뮤노메딕스, 인코오포레이티드 | 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법 |
| WO2004001007A2 (en) * | 2002-06-21 | 2003-12-31 | Idec Pharmaceuticals Corporation | Buffered formulations for concentrating antibodies and methods of use thereof |
| SI1543038T2 (sl) * | 2002-09-11 | 2020-12-31 | Genentech, Inc. | Čiščenje proteinov |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| JP2006511532A (ja) | 2002-12-13 | 2006-04-06 | ミトラ、メディカル、テクノロジー、アクチボラグ | 三官能性試薬によって連結された、エフェクター機能および親和性機能を有する抗リンパ腫ターゲティング剤 |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| NZ554885A (en) | 2002-12-31 | 2009-07-31 | Altus Pharmaceuticals Inc | Complexes of hgh crystals and protamine polymers |
| WO2004087761A1 (ja) * | 2003-03-31 | 2004-10-14 | Kirin Beer Kabushiki Kaisha | ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製 |
| CA2525251C (en) | 2003-05-09 | 2015-10-27 | Duke University | Cd20-specific antibodies and methods employing same |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| US20050079184A1 (en) | 2003-08-08 | 2005-04-14 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| KR100524074B1 (ko) | 2003-10-01 | 2005-10-26 | 삼성전자주식회사 | 베젤 구조를 가지는 전자기기 |
| TW200533357A (en) † | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
| CN101022829A (zh) * | 2004-04-16 | 2007-08-22 | 健泰科生物技术公司 | 用抗cd20抗体治疗多软骨炎和多发性单神经炎 |
| AR049021A1 (es) † | 2004-04-16 | 2006-06-21 | Genentech Inc | Tratamiento de trastornos con un anticuerpo que se une a cd20 |
| EP1833970A2 (en) * | 2004-12-22 | 2007-09-19 | Genentech, Inc. | Methods for producing soluble multi-membrane-spanning proteins |
| AU2006223180B2 (en) * | 2005-03-11 | 2011-11-24 | Wyeth Llc | A method of weak partitioning chromatography |
| TWI372763B (en) * | 2005-06-17 | 2012-09-21 | Wyeth Llc | Methods of purifying anti a beta antibodies |
| WO2007028154A2 (en) * | 2005-09-02 | 2007-03-08 | Northwestern University | Encapsulated arsenic drugs |
| WO2007108955A1 (en) * | 2006-03-20 | 2007-09-27 | Medarex, Inc. | Protein purification |
| KR20140071452A (ko) † | 2006-04-05 | 2014-06-11 | 애브비 바이오테크놀로지 리미티드 | 항체 정제 |
| DK2061803T4 (da) * | 2006-08-28 | 2022-12-05 | Ares Trading Sa | Fremgangsmåde til oprensning af fc-holdige proteiner |
| US8620738B2 (en) | 2006-08-31 | 2013-12-31 | Visa U.S.A. Inc | Loyalty program incentive determination |
| CA2682292A1 (en) * | 2007-03-30 | 2008-10-09 | Medimmune, Llc | Aqueous formulation comprising an anti-human interferon alpha antibody |
| CN101889025B (zh) * | 2007-10-30 | 2013-11-13 | 健泰科生物技术公司 | 通过阳离子交换层析进行的抗体纯化 |
| WO2015198451A1 (ja) | 2014-06-26 | 2015-12-30 | 楽天株式会社 | 情報処理装置、情報処理方法及び情報処理プログラム |
-
2008
- 2008-10-29 CN CN200880119331XA patent/CN101889025B/zh active Active
- 2008-10-29 CN CN201510941252.9A patent/CN105315323A/zh active Pending
- 2008-10-29 WO PCT/US2008/081516 patent/WO2009058812A1/en not_active Ceased
- 2008-10-29 ME MEP-2015-34A patent/ME02101B/me unknown
- 2008-10-29 CL CL2008003218A patent/CL2008003218A1/es unknown
- 2008-10-29 BR BRPI0817182 patent/BRPI0817182A2/pt not_active Application Discontinuation
- 2008-10-29 EP EP12189190.7A patent/EP2565206B1/en active Active
- 2008-10-29 KR KR1020107011765A patent/KR101241486B1/ko active Active
- 2008-10-29 PE PE2008001848A patent/PE20091434A1/es active IP Right Grant
- 2008-10-29 ES ES14189095.4T patent/ES2666170T3/es active Active
- 2008-10-29 EP EP14189095.4A patent/EP2840090B1/en active Active
- 2008-10-29 CA CA2703279A patent/CA2703279C/en active Active
- 2008-10-29 HU HUE08844379A patent/HUE024877T2/en unknown
- 2008-10-29 EP EP08844379.1A patent/EP2215117B2/en active Active
- 2008-10-29 PL PL08844379T patent/PL2215117T5/pl unknown
- 2008-10-29 AU AU2008318865A patent/AU2008318865B2/en active Active
- 2008-10-29 JP JP2010532193A patent/JP5237382B2/ja active Active
- 2008-10-29 CN CN201310495290.7A patent/CN103554215B/zh active Active
- 2008-10-29 PL PL14189095T patent/PL2840090T3/pl unknown
- 2008-10-29 HU HUE12189190A patent/HUE027668T2/en unknown
- 2008-10-29 SI SI200831634A patent/SI2565206T1/sl unknown
- 2008-10-29 NZ NZ584839A patent/NZ584839A/en unknown
- 2008-10-29 RS RS20150156A patent/RS53850B2/sr unknown
- 2008-10-29 ES ES08844379.1T patent/ES2533266T5/es active Active
- 2008-10-29 US US12/260,623 patent/US20090148435A1/en not_active Abandoned
- 2008-10-29 DK DK14189095.4T patent/DK2840090T3/en active
- 2008-10-29 HU HUE14189095A patent/HUE037409T2/hu unknown
- 2008-10-29 DK DK08844379.1T patent/DK2215117T4/en active
- 2008-10-29 KR KR1020147036127A patent/KR20150008503A/ko not_active Ceased
- 2008-10-29 DK DK12189190.7T patent/DK2565206T3/en active
- 2008-10-29 PL PL12189190T patent/PL2565206T3/pl unknown
- 2008-10-29 KR KR1020127028627A patent/KR20140015166A/ko not_active Ceased
- 2008-10-29 SG SG10201401690XA patent/SG10201401690XA/en unknown
- 2008-10-29 SI SI200831945T patent/SI2840090T1/en unknown
- 2008-10-29 AR ARP080104725A patent/AR069097A1/es active IP Right Grant
- 2008-10-29 MX MX2010004740A patent/MX2010004740A/es active IP Right Grant
- 2008-10-29 HR HRP20150282TT patent/HRP20150282T4/hr unknown
- 2008-10-29 ES ES12189190.7T patent/ES2572958T3/es active Active
- 2008-10-29 TW TW103117553A patent/TWI554517B/zh active
- 2008-10-29 EP EP18151178.3A patent/EP3441402A1/en not_active Withdrawn
- 2008-10-29 SI SI200831381T patent/SI2215117T2/en unknown
- 2008-10-29 PT PT88443791T patent/PT2215117E/pt unknown
- 2008-10-29 RU RU2010121816/10A patent/RU2498991C2/ru active
- 2008-10-29 TW TW097141614A patent/TWI448330B/zh active
- 2008-10-29 SG SG2011073087A patent/SG175597A1/en unknown
-
2010
- 2010-04-22 ZA ZA2010/02850A patent/ZA201002850B/en unknown
- 2010-04-25 IL IL205310A patent/IL205310A0/en unknown
- 2010-05-21 CO CO10061141A patent/CO6280422A2/es active IP Right Grant
-
2011
- 2011-03-23 ZA ZA2011/02169A patent/ZA201102169B/en unknown
-
2013
- 2013-03-21 JP JP2013059102A patent/JP2013173747A/ja not_active Withdrawn
- 2013-06-03 PH PH12013501128A patent/PH12013501128A1/en unknown
-
2014
- 2014-09-30 IL IL234902A patent/IL234902A0/en unknown
- 2014-09-30 IL IL234901A patent/IL234901A0/en unknown
- 2014-11-03 US US14/531,880 patent/US9896478B2/en active Active
-
2015
- 2015-02-19 JP JP2015030880A patent/JP5885864B2/ja active Active
- 2015-02-19 JP JP2015030881A patent/JP2015155406A/ja not_active Withdrawn
- 2015-03-19 CY CY20151100275T patent/CY1116129T1/el unknown
- 2015-06-18 IL IL239495A patent/IL239495B/en not_active IP Right Cessation
-
2016
- 2016-07-12 JP JP2016137986A patent/JP2017019790A/ja active Pending
- 2016-08-08 HK HK16109407.0A patent/HK1221234A1/zh unknown
-
2017
- 2017-12-21 US US15/850,885 patent/US20180118781A1/en not_active Abandoned
-
2018
- 2018-03-09 AR ARP180100555A patent/AR111171A2/es unknown
- 2018-06-18 HR HRP20180943TT patent/HRP20180943T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02101B (me) | Pročišćavanje antitijela hromatografijom izmjene katjona | |
| HRP20171095T4 (hr) | Postupci pročišćavanja polipeptida | |
| US10053489B2 (en) | Method for purifying antibody | |
| JP6580650B2 (ja) | フロースルー式での生物製剤からのタンパク質凝集体の除去 | |
| RU2019109975A (ru) | Способы очистки антител | |
| HRP20190485T4 (hr) | Kromatografija preopterećenja i elucijska kromatografija | |
| US11014129B2 (en) | Methods of cleaning a protein A based affinity chromatography column | |
| JP2014532718A5 (me) | ||
| JP7678863B2 (ja) | クロマトグラフィーにおけるバイオバーデンを低減するための組成物および方法 | |
| TWI395609B (zh) | 免疫球蛋白之純化 | |
| JP2018510867A5 (me) | ||
| HRP20201118T1 (hr) | Izolacija i pročišćavanje prot-il-13 protutijela uporabom protein a afinitetne kromatografije | |
| ES2670827T3 (es) | Proceso para la purificación del factor estimulador de colonias de granulocitos, G-CSF | |
| JP2013530156A5 (me) | ||
| JP5944101B2 (ja) | 非グリコシル化タンパク質の精製 | |
| RU2014130017A (ru) | Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии | |
| JP2015520667A (ja) | クロマトグラフィー法 | |
| JP2014507368A5 (me) | ||
| RU2014121886A (ru) | Устройство для обработки курительного изделия и картридж для него | |
| FI3395423T3 (fi) | Vuotaneen affiniteettipuhdistusligandin poistaminen | |
| JP2025186290A (ja) | クロマトグラフィー樹脂の再生方法 | |
| Westra et al. | Immobilised metal-ion affinity chromatography purification of histidine-tagged recombinant proteins: a wash step with a low concentration of EDTA | |
| DE10155984A1 (de) | Verfahren zur Reduktion des Liganden-leakage von Affinitätschromatographie-Matrices | |
| KR20220101168A (ko) | 이온 교환 크로마토그래피 동안 항체의 수율을 증가시키는 방법 | |
| KR20220103967A (ko) | 항체 크로마토그래피 동안의 용리액 수집 |